In 138 adults with moderately to severely active Crohn's disease, week-14 endoscopic response was 26% with duvakitug 450 mg and 48% with 900 mg vs 13% with placebo; both doses met the Bayesian success threshold (posterior probability 0·94 and >0·99).
RCTn = 139
Jairath et al. Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial